Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition: Trends in Immunology
EZH2: a novel target for cancer treatment | Journal of Hematology & Oncology | Full Text
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer | Nature Cancer
The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations | Future Medicinal Chemistry
Frontiers | EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study - The Lancet Oncology
The Phase II EZH2 Inhibitor Trial
Current clinical trials for EZH2 inhibitors. | Download Table
EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation - ScienceDirect
Current clinical trials for EZH2 inhibitors. | Download Table
Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer
Frontiers | EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers
An overview of the development of EED inhibitors to disable the PRC2 function - RSC Medicinal Chemistry (RSC Publishing) DOI:10.1039/D1MD00274K
Frontiers | Easy or Not—The Advances of EZH2 in Regulating T Cell Development, Differentiation, and Activation in Antitumor Immunity
Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis | Cell Death Discovery
Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2–EED Interaction | Journal of Medicinal Chemistry
Clinical studies involving EZH2 inhibitors in haematological neoplasms | Download Table
EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma | PLOS ONE
Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer - ScienceDirect
Known EZH2 inhibitors. GSK126, tazemetostat and CPI-1205 are in... | Download Scientific Diagram
Inhibition of EZH2 (Enhancer of Zeste Homolog 2) Attenuates Neuroinflammation via H3k27me3/SOCS3/TRAF6/NF-κB (Trimethylation of Histone 3 Lysine 27/Suppressor of Cytokine Signaling 3/Tumor Necrosis Factor Receptor Family 6/Nuclear Factor-κB) in a Rat Model
The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review | SpringerLink
SAM-competitive EZH2 inhibitors in clinical trials | Download Scientific Diagram
Histone-writer cancer drugs enter center stage | Nature Biotechnology
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study - The Lancet Oncology
Pre-clinical studies of EZH2 inhibitors in MM | Download Table
Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype | Clinical Epigenetics | Full Text
Global EZH2 Inhibitor Market Opportunity, Sales & Clinical Trials Insight 2026
